CVRx, Inc. Enrolls First Patient in HOPE4HF(TM) Clinical Trial
10/1/2009 9:27:13 AM
MINNEAPOLIS--(BUSINESS WIRE)--CVRx, Inc. reported the first enrollment of a patient in the HOPE4HF Trial, a study that is evaluating the Rheos System to treat heart failure. The Rheos System uses Baroreflex Activation Therapy® technology, an entirely new non-pharmaceutical approach designed to treat cardiovascular disease. The HOPE4HF Trial is being conducted under an approved investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA). Data from this pivotal trial are intended to support a Pre-Market Approval (PMA) application to the FDA for use of the Rheos System in heart failure.
comments powered by